Thrombopoietin receptor agonists: ten years later

Walied Ghanima,1,2 Nichola Cooper,3 Francesco Rodeghiero,4 Bertrand Godeau5 and James B. Bussel6

1Departments of Medicine, Hematology-Oncology and Research, Østfold Hospital Trust, Norway; 2Department of Hematology, Institute of Clinical Medicine, University of Oslo, Norway; 3Department of Medicine, Hammersmith Hospital, Imperial College, London, UK; 4Hematology Project Foundation and Department of Cell Therapy and Hematology, S. Bortolo Hospital, Vicenza, Italy; 5Department of Internal Medicine, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, UPEC, Créteil, France and 6Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA

ABSTRACT

The two thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, were licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then, their use has progressively increased around the world; they are currently used in more than 100 countries. The six largest randomized controlled trials conducted in ITP have used one of these two agents. All studies have demonstrated a platelet response rate between 50-90%, depending on the criteria used, with good safety and tolerability. TPO-RA were shown to be effective in reducing bleeding and the need for concomitant or rescue medication. Many other investigations of their mechanism of effect, prospective and retrospective trials, and studies focusing on toxicity have been performed widening our knowledge of these two agents. Initial concerns on issues such as myelofibrosis have not been confirmed. Only a small number of patients develop moderate-severe reticulin fibrosis and/or collagen fibrosis; however, these are usually reversed after discontinuation of TPO-RA. Studies indicate, however, that TPO-RA may increase the risk of venous thromboembolism. Both TPO-RA are currently approved in patients with chronic ITP aged >1-year who are refractory to at least one other treatment. Eltrombopag has acquired two additional indications: severe aplastic anemia refractory to first-line treatment and hepatitis C patients undergoing treatment with interferon-ribavirin. Despite these wide-ranging studies, important questions still need to be answered. This summary review on TPO-RA will summarize what is known regarding efficacy in ITP, evaluate safety concerns in more depth, and focus on the questions that remain.

Introduction

Over the last 20 years, and before the regular availability of thrombopoietin receptor agonists (TPO-RA), the most commonly used second-line treatments for patients with immune thrombocytopenia (ITP) were splenectomy and rituximab. Both options have the potential to provide a cure. However, long-term responses are not completely satisfactory (60% after splenectomy and only 20% 2-5 year long-term responses after rituximab). Adverse events following these interventions are also significant, if uncommon: post-operative morbidity and increased risk of infections and thromboembolism (TE) after splenectomy, and very rare cases of progressive multifocal leukoencephalopathy (PML) and slight increased infectious rates after rituximab.

The two TPO-RA, romiplostim and eltrombopag, represent a completely different approach to ITP; they both have a very good chance of supporting the platelet count with undemanding daily or weekly treatment. Their goal is to support the patient’s platelet count until adequate levels are achieved and treatment is no
longer required. The TPO-RA were licensed in the US for the treatment of ITP in 2008, and, since then, their use has progressively increased around the world; they are currently used in more than 100 countries. Their introduction heralded a paradigm shift in the treatment of ITP. They are now widely used and many hematologists are well-acquainted with them. This is the 10-year anniversary of their licensure in the US for ITP and it seems appropriate to review the state of the art of these agents: what is known about their mechanism of effect, efficacy, and toxicity, and what remains to be learned, including an exploration of other clinical situations in which they might be useful.

**Mechanism of action**

Romiplostim and eltrombopag both bind to the thrombopoietin (TPO) receptor, causing conformational change in the TPO receptor, activation of the JAK2/STAT5 pathway, and a resulting increased megakaryocyte progenitor proliferation and increased platelet production. However, there are some differences between the two agents (Figure 1). Romiplostim is a peptibody that binds directly and competitively at the TPO binding site, whereas eltrombopag is a small molecule which binds at a transmembrane site. There are also differences in the activation of other signaling pathways in megakaryocytes (MK) such as STAT3, ERK and AKT (Table 1). Additionally, romiplostim mostly stimulates mature precursors, while eltrombopag appears to act earlier in the pathway, stimulating MK precursor cells and MK differentiation. In addition to differences in TPO-receptor activation, eltrombopag also has off-target effects. For example, eltrombopag chelates both extra- and intra-cellular calcium and iron and can shuttle iron out of cells. The iron-chelating action of eltrombopag causes anti-proliferative effects on leukemic cells lines, and a TPO-independent effect on stimulating stem cells and MK precursors in vivo. These differences may explain why some patients respond to one agent and not the other, and why treatment with both agents can be useful in very refractory patients.

Although the prime mechanism of action of the TPO-
RA is thought to be due to increased platelet production, both TPO-RA have also been described to have immunomodulatory effects, with increased regulatory T- and B-cell effects in patients on TPO-RA. This effect has been suggested to be mediated by TGF-B, a major cytokine involved in T-regulatory (Treg) cell development, and found in abundance in MK and platelets. Alternatively, TPO-RA may also affect antigen processing and presentation by MK. Whether these potential immunomodulatory effects result in the treatment-free durable responses reported with both TPO-RA has not yet been understood.

**Efficacy of romiplostim and eltrombopag**

**Platelet response**

The response rate of these agents depends on the definition of “response.” If a consistent “durable” platelet count response is required, then the response rate may be 40-60%. This type of response, with platelet counts consistently higher than 50x10⁹/L without bleeding and/or need for rescue therapy, is a realistic goal for patients with ITP. If, however, a “response” is a single platelet count over 50x10⁹/L during a finite period of time, then the response rate is closer to 60-90%. Platelet response rates reported with both TPO-RA has not yet been understood.

**Table 1. Characteristics and down-stream effect of eltrombopag, romiplostim and endogenous thrombopoietin.**

<table>
<thead>
<tr>
<th></th>
<th>Eltrombopag</th>
<th>Romiplostim</th>
<th>Thrombopoietin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Structure and discovery</td>
<td>Small molecule discovered by screening libraries of small molecules that stimulate the TPO receptor down-stream pathways</td>
<td>Peptibody developed by screening peptide libraries for sequences that can stimulate the TPO receptor</td>
<td></td>
</tr>
<tr>
<td>Binding site</td>
<td>Binds the transmembrane and juxtamembrane domains of the TPO receptor</td>
<td>Binds to the extracytoplasmic domain of the TPO receptor in same manner as TPO</td>
<td>Acts at TPO binding site</td>
</tr>
<tr>
<td>Effect on endogenous thrombopoietin</td>
<td>No displacement of TPO, may be additive</td>
<td>Can displace TPO from its receptor</td>
<td></td>
</tr>
<tr>
<td>Demonstrated down-stream effect on various signal pathways*</td>
<td>JAK2/STAT5, PI3K/Akt, ERK</td>
<td>JAK2/STAT5, PI3K/Akt, ERK</td>
<td>JAK2/STAT5, PI3K/Akt, ERK</td>
</tr>
<tr>
<td>Effect on MK</td>
<td>Earlier MK (including CD41) and late MK</td>
<td>Mature MK (CD41⁺ CD61⁺)</td>
<td>All stages</td>
</tr>
<tr>
<td>Off-target effect</td>
<td>Iron and Ca chelation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Reduction in bleeding and concomitant medications**

The meta-analysis showed that TPO-RA significantly reduced incidences of any or severe bleeding events (RR: 0.8, 95% CI: 0.7-0.9; RR: 0.5, 95% CI: 0.3-0.99, respectively). Especially with eltrombopag, there were substantial reductions in any or severe bleeding events in treated patients compared with controls (RR: 0.7, 95% CI: 0.5-0.9; and RR: 0.3, 95% CI: 0.1-1.0, respectively). In parallel with reduced bleeding episodes, pooled results of eight studies indicated a significant reduction in the need for rescue medications in the TPO-RA groups compared with control groups (RR: 0.5, 95% CI: 0.4-0.6). Treatment studies with both agents have also demonstrated an ability to reduce or stop concomitant medications (RR: 1.8, 95% CI: 1.1-3.0).

**Health-related quality of life and thrombopoietin treatment**

Health-related quality of life (HRQoL) was studied in many of the RCT and extension studies conducted with

---

1. TPO: thrombopoietin; MK: megakaryocytes; Ca: calcium. *Not all pathways have been fully explored.
TPO-RA using different generic and disease-specific questionnaires. Unquestionably, ITP has a major negative impact on HRQoL.\(^{28,29}\)

In general, short-term treatment with TPO-RA does not seem to affect HRQoL,\(^{19,22}\) while long-term studies with both agents show improvements in HRQoL.\(^{17,25}\) In the open-label RCT comparing romiplostim to SoC, clinically significant improvement in seven scales of the Immune Thrombocytopenic Purpura Patient Assessment Questionnaire (ITP-PAQ) was observed in both treatment arms at 52 weeks compared with baseline.\(^{17}\) However, the romiplostim group, and in particular the responders, had

<table>
<thead>
<tr>
<th>Comparator arm</th>
<th>Study duration</th>
<th>Definition of the primary end point for efficacy</th>
<th>Primary end point</th>
<th>Any increase in plate count</th>
<th>Bleeding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Romiplostim</td>
<td></td>
<td>Proportion of patients achieving platelet count (\geq 50 \times 10^9/L)</td>
<td>75% had platelet counts that reached or exceeded the targeted range vs. 25% in the placebo group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bussel(^{19})</td>
<td>Placebo</td>
<td>Proportion of patients achieving platelet count (\geq 50 \times 10^9/L) during (\geq 6) of the last 8 weeks of treatment</td>
<td>38% of splenectomized patients given romiplostim vs. 0% given placebo; (P=0.0013), and 61% of non-splenectomized given romiplostim vs. 5%; (P&lt;0.0001)</td>
<td>Overall platelet response rate was noted in 88% of non-splenectomized and 79% of splenectomized patients given romiplostim compared with 14% of non-splenectomized and 0% splenectomized patients given placebo; (P&lt;0.0001)</td>
<td>Significant bleeding events were reported in 12% of the patients in the placebo group and 7% in the romiplostim group</td>
</tr>
<tr>
<td>Kuter(^{17})</td>
<td>Placebo</td>
<td>Incidences of treatment failure and splenectomy</td>
<td>11% in romiplostim arm vs. 30% in SoC arm (OR 0.31; 95% CI: 0.15-0.61; (P&lt;0.0001))</td>
<td>Between weeks 2 and 52 a 71-92% platelet response in the romiplostim group and 26-51% in the SoC</td>
<td>Romiplostim group had significantly lower adjusted incidences of overall bleeding events ((P=0.001)) and bleeding events of grade 3 or higher ((P=0.02)) vs. the SoC</td>
</tr>
<tr>
<td>Shirasugi (^{88})</td>
<td>Placebo</td>
<td>Number of weeks with platelet response, defined as a platelet count (\geq 50 \times 10^9/L) (not including the 4 weeks after administration of rescue medication)</td>
<td>Weekly responses occurred for a median of 11 weeks with romiplostim vs. 0 weeks with placebo; (P&lt;0.0001)</td>
<td>95% of romiplostim-treated patients achieved platelet responses</td>
<td></td>
</tr>
</tbody>
</table>

| Eltrombopag         |                | Proportion of patients achieving platelet counts \(\geq 50 \times 10^9/L\) at day 43       | 28-81\% response depending on the dose vs. 11\% in the placebo arm; \(P<0.001\) |                             |                                                                          |
| Bussel\(^{21}\)      | Placebo        | Proportion of patients achieving platelet counts \(\geq 50 \times 10^9/L\) at day 43       | 59\% in eltrombopag 16\% in placebo arms, OR 9.61; 95\% CI: 3.31-27.86; \(P<0.0001\) | Patients in the eltrombopag group also had significantly greater odds of responding at any point during the 6-week treatment period than did those in the placebo arm; OR 8.79; 95\% CI: 3.54-21.86; \(P<0.0001\) |                                                                          |
| Cheng\(^{25}\)       | Placebo        | OR of response defined as a platelet count of 50-400x10^9/L                              | 79\% vs. 28\% OR 8.2; 95\% CI: 3.58-18.73; \(P<0.0001\)                            |                             |                                                                          |
| Toshiyama\(^{89}\)   | Placebo        | Platelet count of \(\geq 50 \times 10^9/L\) at week 6 of the 6-week cycle             | 60\% in eltrombopag-treated patients; 0\% in placebo-treated patients            |                             |                                                                          |

w: week; m: month; SoC: Standard of Care; OR: Odds Ratio; CI: Confidence Interval.
significantly greater improvements, although the magnitude of the effect was of uncertain clinical benefit. In the RAISE study, HROQol was significantly improved in the eltrombopag arm only, in five of the eight SF-36 domains at week 26 compared to baseline. In the EXTEND trial, all the HROQol instruments used had positive mean changes from baseline over time. The improvements from baseline persisted through five years of treatment. This study found positive and clinically-meaningful mean changes from baseline in all HROQol scores.

Practical issues related to use of thrombopoietin receptor agonists

Indication and dosage

The current label for both TPO-RA in Europe and in the US is patients aged ≥1 year with chronic ITP who are refractory to at least one other treatment (e.g. corticosteroids, immunoglobulins).

Initial dosing with eltrombopag starts at 50 mg daily, unless the patient is East Asian in whom a lower dose should initially be used. If a response is not seen in two weeks, the dose is increased to 75 mg daily, the maximum dose licensed for ITP. In the RAISE study of 197 adults, approximately equal numbers of patients were on 50 and 75 mg daily after six months of treatment. With romiplostim, the package insert recommends 1 μg/kg/week and increasing by 1 μg/kg/week until a response is achieved; however, this approach would take nine weeks to achieve the maximum dose of 10 μg/kg/week. A more practical schema would be to start at 3 μg/kg/week, particularly if a rapid response is needed, or one full vial of 250 μg, and increasing weekly to 5, 7, and then 10 μg/kg/week until a response is achieved. Median dose of romiplostim in adults is 3-5 μg/kg/week. In Europe, approximately one-third of the patients self-administer romiplostim subcutaneously. In the US, self-administration is still not licensed; however, this appears likely to be allowed in the near future.

In the pediatric studies, many children needed the maximum dose of 10 μg/kg/week of romiplostim and 75 mg of eltrombopag, which corresponds to 5-6 mg/kg as compared to 0.5-1 mg/kg for adults.

Choice of agent

The two TPO-RA have comparable overall efficacy. Eltrombopag is given orally while romiplostim is dosed as a weekly subcutaneous injection. However, eltrombopag must be given on an empty stomach; in particular, it should be taken four hours after and two hours before food containing cations, e.g. iron, calcium, milk or other dairy products. In the US, different criteria for medical insurance are used for the two agents, which may impact on the decision to adopt one treatment or the other depending on which is likely to be approved first. If patients have absorption problems or transaminitis, it may be prudent to use romiplostim. If patients do not have stable platelet counts, or if they do not want to come to the clinic every week for injections, then eltrombopag may be better.

Dealing with non-responders: switching or combination

Approximately one-third of the patients discontinue TPO-RA because of lack of response. If one TPO-RA does not work, switching to the other TPO-RA has been seen to be surprisingly effective. In a study of 46 patients who switched from one agent to another, 80% of the patients who failed to respond to eltrombopag eventually responded to romiplostim, and 46% of patients who did not respond to romiplostim responded to eltrombopag. These results were confirmed in a more recent retrospective study in which 106 patients underwent switching with 60% achieving response with either agent after switching. Switching can also be an effective policy in case of severe platelet-count fluctuations or side-effects. Finally, stopping one agent before starting the other is not essential, unless adverse effects are the indication to switch (W Ghanima et al., personal observation, 2019). The addition of a small dose of steroid (2.5-5 mg prednisolone) to a TPO-RA may have a good effect in some patients and can be tried in non-responding patients (W Ghanima et al., personal observation, 2019).

Treatment-free durable responses after discontinuation of thrombopoietin receptor agonists

Approximately 10-30% of patients taking a TPO-RA will be able to discontinue their TPO-RA and maintain response after discontinuation. In one study of 75 adults with ITP of <6 months duration treated with romiplostim for ≥12 months, 32% were able to discontinue the medication and to obtain treatment-free durable responses (platelet counts >50x10^9/L) lasting at least six months. Higher mean platelet count (138x10^9/L) for the first two months was associated with remission. However, lasting treatment-free response has also been reported in chronic patients. In a retrospective study, 10% of 260 patients treated with eltrombopag maintained acceptable platelet counts after discontinuation of the drug. In another small retrospective study of 54 patients who were treated with TPO-RA for at least five years, TPO-RA were discontinued in 20 out of 28 patients who achieved a complete response. Of these, eight patients showed a sustained response for a median of 13 months (range 5-27 months). However, it is still not known how TPO-RA induce long-lasting off-treatment responses, although it is unlikely that this is simply due to a selection of patients who would eventually remit. Durable responses have even been observed in patients with long-lasting disease. Potential mechanisms include: restored immune tolerance by increased exposure to platelet autoantigens, thereby reducing platelet antibodies through increased presence of MK and platelets, or through improvement of Treg function, which in turn could restore immune tolerance to platelets.

Predicting who will achieve a durable response and how to discontinue TPO-RA is challenging. We recommend tapering in a patient who achieves and maintains a stable platelet count over 50-100x10^9/L for at least 3-6 months, particularly if using low doses of a TPO-RA and achieving a normal, stable platelet count for some months. One way to taper treatment would involve gradually decreasing and/or increasing the interval between doses until the platelet count remains <30x10^9/L or it is possible to discontinue treatment.

Safety and tolerability of thrombopoietin receptor agonists

Ten years after their availability, TPO-RA have been proven to be well-tolerated. The long follow up of the
patients included in the pivotal studies and "real-life" reports generally give reassuring data. Many of the initial theoretical concerns, such as uncontrolled stem cell proliferations and myelofibrosis with TPO-RA, have not materialized. However, there are emerging reports of adverse events, such as an increased incidence of thrombosis, which remains unexplained.

In the EXTEND study, evaluating long-term safety and efficacy of eltrombopag in 302 adults ITP patients treated with eltrombopag for a mean duration of >2 years, important adverse events were rare and did not increase with treatment duration over one year.²⁴ Fourteen percent of patients on eltrombopag stopped treatment because of adverse events. Although plasma levels and exposure have been shown to be much higher in Asian populations,⁶⁰ tolerability of eltrombopag in the Chinese population appears similar to that observed in Caucasian populations. The good tolerance of eltrombopag observed in pivotal studies has been confirmed in the Spanish eltrombopag registry including 220 ITP adults.⁶¹

In a pooled analysis from 13 completed studies of romiplostim including 1111 patients, exposure-adjusted rates of adverse events were lower in the romiplostim group than in the placebo/SoC group.⁶² These data were confirmed in another registry study.⁶³

Bone marrow reticulin deposition and TE events are associated with the TPO-RA drug class. However, the safety profiles of TPO-RA do not fully overlap and specific adverse events, i.e. cataract and transaminitis, are more frequently seen with eltrombopag. Others, such as development of neutralizing antibodies, are mainly observed with romiplostim, as is pain after administration. This absence of overlapping toxicity encourages switching when a TPO-RA is stopped because of an adverse event that is not due to class effect.

**Bone marrow fibrosis**

Early concerns were raised regarding the possible induction of bone marrow fibrosis because of sustained stimulation of megakaryopoiesis by TPO-RA, as seen in animal studies.⁶⁴ Table 3 summarizes results of the published trials showing that, in most patients, grade of fibrosis decreased after treatment with any of the TPO-RA during the period of treatment.

### Table 3. Summary of studies determining the grade of bone marrow fibrosis in patients treated with thrombopoietin receptor agonists.

<table>
<thead>
<tr>
<th>Author</th>
<th>Study design</th>
<th>N</th>
<th>Agent</th>
<th>Staging</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ghanima⁴⁸</td>
<td>Retrospective, single center. BM biopsies were performed at different intervals.</td>
<td>66</td>
<td>R, E</td>
<td>ECS</td>
<td>After a median treatment duration of 29 months (range: 16-47), 22% of the BM biopsies were graded as MF-0, 59% as MF-1 and 18% as MF-2. The proportion of MF-0 decreased from 67% in the pre-treatment biopsies to 22% first on-treatment biopsies, which were largely MF-1. Two or more biopsies were available in 32 patients; comparing the first to the last on-treatment bone marrows, the grade of fibrosis increased in 11 cases, remained the same in 15 and decreased in 6.</td>
</tr>
<tr>
<td>Brynes⁴ⁱ</td>
<td>Prospective, open-label multicenter study of patients who were included in the EXTEND trial and received eltrombopag were followed up with annual BM biopsies</td>
<td>117</td>
<td>E</td>
<td>ECS</td>
<td>209 on-treatment biopsies collected from 115 patients were re-evaluated. Median duration of treatment was 45 months (range: 2-73m). 98% of patients had findings of MF-0 or MF-1 in any given year over the 5-year study period. Five biopsies from 3 patients (2%) were reported as MF-2 or MF-3 at 25 months; collagen was present in these 5 specimens. Of 18 patients with 3 biopsies, 8 patients remained at MF-0 over the treatment period and 5 had an increase of one grade. The remaining 5 patients showed a decrease of one grade when compared with the grade from the first on-treatment biopsies.</td>
</tr>
<tr>
<td>Brynes⁴ⁱ</td>
<td>Prospective, open-label multicenter. Biopsy specimens were collected at baseline (before treatment) and after 1 and 2 years of treatment</td>
<td>162</td>
<td>E</td>
<td>ECS</td>
<td>Median time on treatment was 104 weeks (range: 2.4-113). At 1 year (n=127), 69% had a grade of MF-0, 28% had MF-1, 2% had MF-2, and 2% had MF-3. Compared with baseline, 79 out of 93 patients (85%) had MF-0 at 2 years, 9 (10%) had a 1-grade increase, 2 (2%) had a 1-grade decrease, 1 (1%) remained MF-1, and none had 2- or 3-grade increases. Five out of 127 patients (4%) at 1 year and 1 out of 93 (1%) at 2 years had collagen deposition.</td>
</tr>
<tr>
<td>Janssens⁵⁰</td>
<td>Prospective, open-label multicenter. Bone marrow biopsies were scheduled after 1, 2, or 3 years of romiplostim or earlier if patients discontinued or failed to achieve/maintain a response to romiplostim.</td>
<td>131</td>
<td>R</td>
<td>Bauermeister</td>
<td>The median (Q1, Q3) duration of treatment was in cohort 1, 147 (17-156) weeks; cohort 2, 155 (66, 156) weeks; and cohort 3, 155 (66-156) weeks. 9 of 131 (6.9%) included in the 3 cohorts had increases of ≥2 grades (cohort 1: 0/34; cohort 2: 2/39; cohort 3: 1/58), including 2 with collagen.</td>
</tr>
</tbody>
</table>

R: romiplostim; E: eltrombopag; ECS: European Consensus Staging; BM: bone marrow; MF: marrow fibrosis.
sis did not change during treatment with TPO-RA, while a slight, non-progressive reticulin fibrosis (MF-1 or Baumeister <2) was observed in 10-50% of patients. In one study, a moderate increase in reticulin fibrosis (MF-2) was observed in 18% at median time of treatment of 2.5 years, whereas in three other studies, reticulin fibrosis progressed by >2 grades or developed MF-2 during the study periods in less than 10%. Severe grades of reticulin fibrosis (MF-3 and/or collagen fibrosis) were extremely rare in all studies. In general, it does not seem that TPO-RA induce substantial fibrosis or changes in number or morphology of peripheral blood cells. Both reticulin and collagen fibrosis regressed in most patients after discontinuation of TPO-RA; in a few patients, fibrosis regressed despite continuing therapy.

There is no consensus for patients on TPO-RA as to whether or how to monitor bone marrow (BM) fibrosis. At the moment, hardly any centers perform routine BM biopsy in TPO-RA treated patients. However, if a biopsy is performed and severe reticulin (MF3) or collagen is discovered, then it is recommended that TPO-RA be discontinued. With moderately increased fibrosis, e.g. MF 2, a patient may continue TPO-RA but may need a repeat biopsy in six months. Older age and splenectomy could be associated with higher grades of BM fibrosis; fibrosis was not associated with type, dose or duration of treatment.

**Risk of clonal evolution and malignancy**

The TPO-receptor is expressed in many hematopoietic cells, including early stem cells. Sustained stimulation of the hematopoietic cells raised concerns regarding potential clonal evolution associated with prolonged use of TPO-RA. Based on clinical trials, safety databases and ten years of clinical experience, there are no indications that TPO-RA induce neoplastic changes in ITP patients. A safety analysis of more than 1000 patients treated with romiplostim showed that rates of hematologic and non-hematologic malignancies were comparable between the romiplostim group and the placebo/SoC. In the EXTEND study, ten (5%) patients reported malignancies diagnosed during the 6-year study. In one ITP study, routine BM flow cytometry and cytogenetic studies were performed and no karyotypic or immunophenotypic changes indicative of monoclonality were detected.

**Thromboembolism**

In early trials with TPO-RA, sporadic thromboembolic events (TEE) gave impetus to extensive epidemiological studies exploring the association between thrombosis and ITP and the role of TPO-RA. The incidence of TEE in patients with chronic ITP not exposed to TPO-RA was compared with age- and sex-matched non-ITP control patients, described in n. 5 of Table A and n. 14 of Table B; 22 children enrolled in a double-blind study, and patients directly enrolled in different open-label studies (a large expanded access study, now available as a full paper; a Japanese extension study; a long-term biopsy study).

### Table 4. Incidence of thromboembolism with romiplostim and eltrombopag in long-term studies or in pooled analyses in adults.

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Description</th>
<th>Patients with history or risk factors for TE excluded</th>
<th>N. of patients with TEs</th>
<th>Mean exposure time (years)</th>
<th>Total n. of TEs</th>
<th>First TEE rate per 100 pt-years</th>
<th>All TEE rate per 100 pt-years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Arterial</td>
<td>Venous</td>
<td>Others</td>
<td>Arterial</td>
<td>Venous</td>
<td>Arterial</td>
</tr>
<tr>
<td><strong>Romiplostim</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kuter&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Long-term investigation on 291 pts who completed a previous randomized romiplostim study&lt;sup&gt;*&lt;/sup&gt; (Aug 2004 - Jan 2010)</td>
<td>In most cases, but not invariably</td>
<td>19/291 (6.5%)</td>
<td>2.11</td>
<td>Arterial</td>
<td>25</td>
<td>Venous 2.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Venous</td>
<td>9</td>
<td>Venous 1.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Arterial</td>
<td>3.1</td>
<td>Venous 4.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Venous</td>
<td>4.1</td>
<td></td>
</tr>
<tr>
<td>Rodeghiero&lt;sup&gt;5&lt;/sup&gt;</td>
<td>Pooled analysis of 13 clinical trials&lt;sup&gt;^&lt;/sup&gt; (Oct 2003 and June 2009)</td>
<td>In most cases, but not invariably</td>
<td>38/653 (5.9%)</td>
<td>1.41</td>
<td>Arterial</td>
<td>69</td>
<td>Venous 2.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Venous</td>
<td>40</td>
<td>Venous 4.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Arterial</td>
<td>4.2</td>
<td>Venous 7.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Venous</td>
<td>7.5</td>
<td></td>
</tr>
<tr>
<td><strong>Eltrombopag</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Arterial</td>
<td>2.9</td>
<td>Venous 3.4</td>
</tr>
<tr>
<td>Wong&lt;sup&gt;6&lt;/sup&gt;</td>
<td>Long-term investigation on 302 out of 371 patients completing previous trials fed into this study (June 2006-July 2015)</td>
<td>Yes</td>
<td>19/302 (6.3%)</td>
<td>2.37</td>
<td>(median, range 2 days-8.5 yrs)</td>
<td>Arterial 2.0</td>
<td>Venous 1.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Venous</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

<sup>*</sup>From an interim analysis (Aug 2004-July 2007) describing 142 patients for a mean exposure time of 69 weeks; 12 thromboembolism (TE) events were found in seven patients, with an incidence rate of TE of 6.4/100 patient-years (pt-yrs) (3.7/100 pt-yrs after censoring at the first event). Analysis includes patients completing previous studies conducted in the US, Europe, Canada and Australia (described in studies 2, 3, 4 of Online Supplementary Table S1 and n. 12 and 13 of Online Supplementary Table S2) who were subsequently enrolled in an open label extension study. Only thrombotic events occurring after enrollment in the extension were considered. Analysis includes all 219 patients of Kuter et al., 2013<sup>3</sup> and all of an additional 362 patients, including Japanese patients, described in n. 5 of Table A and n. 14 of Table B. 22 children enrolled in a double-blind study and patients directly enrolled in different open-label studies (a large expanded access study, now available as a full paper; a Japanese extension study; a long-term biopsy study). Details of studies can be found in Rodeghiero et al. The same studies with a later cut off (June 2011) were also analyzed by Cines et al. Also including preliminary data in abstract form of Janssens et al. The analysis of Cines et al. provided a similar thrombotic events rate of 5.5/100 pt-yrs both in the romiplostim (n. 504, 1520 pt-yrs) and in the placebo/Standard of Care (n. 138, 110 pt-yrs) patients. No additional patients who only had TEE off-study (see Table S5) are excluded. N/n: number; TEE: thromboembolic events.
The annualized incidence was 0.41-0.67 for venous thromboembolism (VTE) and 0.96-1.15 for arterial thrombosis (AT), whereas the control populations had 0.28-0.42 and 0.67-0.91, respectively, showing a slightly but statistically significantly higher risk of VTE and possibly AT in ITP patients.63

Thromboembolic events in the long-term studies and pooled analyses are summarized in Table 4. Online Supplementary Table S1 describes thromboembolic events in phase I-II and in randomized, placebo-controlled studies, while Online Supplementary Table S2 refers to single arm trials. As shown in Online Supplementary Table S1, the exposure time to TPO-RA was generally short and ranged from a few weeks to 6 months (or 1 year in a single study).66 Overall, there have been 15 events out of 415 patients exposed to romiplostim (5.6%) versus 4 events in 202 controls (2%), and 5 events in the 391 patients exposed to eltrombopag (1.3%) versus none out of 155 controls. Conversely, more consistent and significant data could be derived from the large long-term studies or pooled analyses mainly based on the long-term extension studies, fed by patients who had completed previous trials and in a single-arm study investigating a large number of patients. These studies included greater numbers of patients and report on longer treatment exposure.24,27,31,35 Notably, patients with history of or important risk factors for thrombosis were excluded upfront from the RCT, and patients experiencing TEE during their previous study were excluded from long-term extension studies, resulting in a generally smaller thrombosis risk population in the long-term studies. Despite that, a relatively large number of TEE occurred in the long-term studies.

The incidence per 100 patient-years (censoring after first TEE) ranged from 3.1 to 4.2 with romiplostim and was 2.9 in the single eltrombopag study. Without censoring after first event, the incidence ranged from 4.1 to 7.5 with romiplostim and 5.4 with eltrombopag.60 In a pooled analysis of romiplostim studies, an incidence rate per 100 patient-years of 5.5 was reported for both patients exposed to eltrombopag (1.3%) versus none out of 155 controls. Conversely, more consistent and significant data could be derived from the large long-term studies or pooled analyses mainly based on the long-term extension studies, fed by patients who had completed previous trials and in a single-arm study investigating a large number of patients. These studies included greater numbers of patients and report on longer treatment exposure.24,27,31,35 Notably, patients with history of or important risk factors for thrombosis were excluded upfront from the RCT, and patients experiencing TEE during their previous study were excluded from long-term extension studies, resulting in a generally smaller thrombosis risk population in the long-term studies. Despite that, a relatively large number of TEE occurred in the long-term studies.

Thrombotic events have also been reported in pediatric trials. In a multicenter retrospective study on 79 children with ITP treated with eltrombopag, romiplostim or both, two cases of pulmonary embolism were reported.64 The randomized controlled trials did not identify any TEE, and overall TEE incidence is clearly lower than in adults.25,33,35,65

The TEE events were neither associated with thrombocytosis nor with a higher dose of TPO-RA. At least 30-50% of cases occurred in patients with lower than normal platelet counts. In general, TEE events tended to happen in the first year of treatment, creating a trend towards lower incidence figures with more prolonged exposure time. Among arterial events, cerebrovascular (stroke) and myocardial (infarction) were predominant and seen more in patients >70 years of age. However, <20% of TEE resulted in permanent disability and only three deaths could be attributed to thrombosis. In a pooled analysis, the annualized risk of thromboembolism in splenectomized patients (6.3) was not significantly higher than non-splenectomized patients (4.3).66

The pathogenic mechanisms responsible for the increased thrombotic risk linked to TPO-RA have not yet been identified.67 The expected findings that TPO-RA lower the threshold of platelet activation have not been demonstrated.68,69 In general, ITP per se seems to be a procoagulant condition, as indicated by an increase in the various coagulation activation markers, including D-dimer, prothrombin fragment F1+2 and thrombin generation, and in the antifibrinolytic marker plasminogen activator inhibitor-1 (PAI-1) compared to controls.70,71 No further increase in the coagulation activation markers has been observed after the initiation of TPO-RA.70,71 However, a recent study reported increased PAI-1 levels in patients treated with TPO-RA, possibly leading to the formation of a more fibrinolysis-resistant clot; the study also showed increased microparticle-associated phosphatidylserine procoagulant activity.72 Moreover, levels of soluble P-selectin and basal exposure of P-selectin in quiescent platelets were significantly increased in TPO-RA treated patients compared to pretreatment levels or to untreated patients; however, the significance of these findings is still not known.72,73

In summary, although they have not been substantiated in properly designed trials, the annualized thrombosis rates in adults appear to be 2-3 times higher (annualized incidence rate of TEE of 4-7%) with TPO-RA treatment than in an ITP population not treated with TPO-RA, and even higher if compared to non-ITP control populations.63 On the other hand, most available data on the risk of thrombosis are based on retrospective and registry studies, which probably underestimate the risk of thrombosis in the ITP population. The patient’s individual risk profile should be considered when initiating treatment with a TPO-RA to evaluate if the expected reduction in bleeding risk outweighs the risk of thrombosis. Comorbidities more prevalent in ITP should be considered and/or investigated; these include previous thromboembolism, splenectomy, presence of antiphospholipid antibodies, and concomitant medications like estrogenic preparations. Efforts should be made to correct modifiable risk factors, and thrombo-prophylaxis is recommended for surgery, provided the patient has a safe platelet count.69 Furthermore, antiplatelet agents or even anticoagulation could be considered in patients at high risk of thrombosis once platelet counts reach >50x10^9/L after initiation of TPO-RA.

Rebound thrombocytopenia

In most patients receiving TPO-RA, platelet counts return to pre-therapy baseline values on discontinuation of therapy; however, in up to 10% of patients, platelet counts temporarily drop below pretreatment levels after discontinuation of TPO-RA.18 Endogenous TPO activity, which is regulated by platelet mass, may be suppressed while platelet and MK levels are elevated on TPO-RA and may not rapidly re-equilibrate when TPO-RA are abruptly discontinued. However, the REPEAT study, which involved intermittent administration of eltrombopag, provided reassuring data.72 Nonetheless, when TPO-RA treatment is discontinued, tapering is preferred to immediate withdrawal.

Fluctuating platelet counts

Substantial fluctuations in platelet count on stable treatment doses may occur and can be difficult to manage. They are more common with romiplostim than eltrombopag, possibly due to the longer dosing intervals and inconsistent delivery with subcutaneous administration.60 Some
patients experiencing such platelet fluctuations with romiplostim can be stabilized by switching to eltrombopag. 74

Adverse events mainly associated with eltrombopag

Cataract
Treatment-related cataracts were observed in juvenile rodents on eltrombopag and were dose and time dependent. Cataracts have been reported with both eltrombopag and romiplostim. Given multiple confounding risk factors, e.g. steroid use, older age, smoking, no clinical study has unequivocally demonstrated this suspected risk with TPO-RA. In a 6-month study, the incidence of cataract in patients treated with eltrombopag was similar to placebo. 23 In the open-label EXTEND study, cataracts developed in 28 patients (9%) in up to eight years of treatment. In 16 (5%), it was considered a severe adverse event, which led to withdrawal of eltrombopag in four (1.3%) patients. 24 In the Pediatric Patients with Thrombocytopenia from Idiopathic Thrombocytopenic Purpura (PETIT2) study, two children developed cataracts, raising serious concern. 35 The analysis of up to 1000 patients treated with romiplostim for ITP reported 37 events of cataracts, but only one case in patients with placebo or SoC, suggesting cataracts, given the big difference in exposure, might also be associated with romiplostim. 46

An alternative option to routine ophthalmological evaluation for all patients on eltrombopag is to reserve ophthalmic examination for patients with one or more risk factors.

Transaminitis
Hepatocyte degeneration, associated with increased serum liver enzymes, was observed in animals at doses that were associated with morbidity and mortality. In humans, development of transaminitis occurs in up to 10%, especially on eltrombopag. 23−25 Bilirubin elevations are also possible but involve mainly non-conjugated bilirubin (not indicative of serious liver injury). Transaminitis is mostly asymptomatic and reversible with dose interruption, reduction or discontinuation; only 3% of children and adults were unable to tolerate eltrombopag in large studies. 23−25 Transaminitis occurs more in the first year of treatment, which justifies regular monitoring of liver enzymes at more frequent intervals particularly during the first years.

Adverse events mainly associated with romiplostim

Risk of antibody development
Romiplostim is a chimeric fusion protein produced by genetic engineering. Neutralizing antibodies directed against romiplostim have been reported. In contrast, because small molecules do not typically elicit an immune response, development of neutralizing antibodies is not considered to be a risk for eltrombopag. In an analysis of up to 1000 patients treated with romiplostim, neutralizing antibodies to romiplostim were reported in only six patients; importantly, none cross-reacted with endogenous TPO. All had a platelet response, and detection of neutralizing antibodies did not automatically result in loss of response. 46 However, neutralizing antibodies were detected in a group of four patients treated with romiplostim who lost response. 75 Current estimates, based on very limited data, suggest that these occur at a rate of up to 1%, more frequently in children than adults. Monitoring could be yearly and when response is lost.

Other indications for thrombopoietin receptor agonists
Treatment of severe aplastic anemia (SAA) with eltrombopag yielded multilineage clinical responses in certain patients with refractory severe aplastic anemia. 71 Consequently, eltrombopag has been approved for use in patients with SAA failing immunosuppression who are not eligible for transplantation. A recent study has shown benefit when eltrombopag was used upfront together with immunosuppression, with more than one-third of the patients achieving a complete response by six months. 72

Thrombocytopenia is a common complication of liver disease, and eltrombopag was licensed to support the platelet count in patients with hepatitis C undergoing treatment with interferon and ribavirin. However, improvements in current hepatitis C therapy have meant that interferon is no longer used. 70 Studies into the use of TPO-RA in MDS are no longer actively pursued, perhaps not so much because of the risk of induction of leukemia, as because of failure to provide evidence of survival benefit. 54−55

The major indication under study is in solid tumor chemotherapy. Studies are now available that demonstrate promising results. Schedule and dosing in solid tumor chemotherapy can be better maintained, but translating this into a survival advantage still has to be clearly demonstrated. 77

Treatment of inherited thrombocytopenias with eltrombopag has been studied in MYH9-related disorders and Wiskott-Aldrich syndrome, showing platelet response in both conditions. 74−80

Other thrombopoietic agents
Two current studies with avatrombopag and lusutrombopag, both of which were recently approved for procedures in thrombocytopenic patients with liver disease in the US, were careful to verify adequate pre-procedure portal flow and use only several days of TPO-RA prior to and during the procedure to avoid risks of thrombosis, especially that of the portal vein. Avatrombopag, an oral small molecule, apparently binds to the TPO-R similarly to eltrombopag, but does not have any dietary limitations. 81 It was shown to be effective in a phase II study of ITP, 81 and also in a recently published phase III trial, which confirmed the superiority of avatrombopag (5-40 mg daily) over placebo with regard to acute and durable platelet response in patients with chronic ITP. Headache was the most frequent side effect. 82 In view of the two RCT in ITP and the approved indication in liver disease, we expect that avatrombopag will be licensed for ITP.

A recombinant human thrombopoietin (rhTPO) has been licensed in China for many years in adults and children with ITP. Studies have also recently been performed in pregnant women, all with good results. 59−64 One concern is the uncertainty regarding development of antibodies to the TPO agent which, unlike those seen with romiplostim, might cross-react with endogenous TPO and create lasting

Other thrombopoietic agents
Two current studies with avatrombopag and lusutrombopag, both of which were recently approved for procedures in thrombocytopenic patients with liver disease in the US, were careful to verify adequate pre-procedure portal flow and use only several days of TPO-RA prior to and during the procedure to avoid risks of thrombosis, especially that of the portal vein. Avatrombopag, an oral small molecule, apparently binds to the TPO-R similarly to eltrombopag, but does not have any dietary limitations. 81 It was shown to be effective in a phase II study of ITP, 81 and also in a recently published phase III trial, which confirmed the superiority of avatrombopag (5-40 mg daily) over placebo with regard to acute and durable platelet response in patients with chronic ITP. Headache was the most frequent side effect. 82 In view of the two RCT in ITP and the approved indication in liver disease, we expect that avatrombopag will be licensed for ITP.

A recombinant human thrombopoietin (rhTPO) has been licensed in China for many years in adults and children with ITP. Studies have also recently been performed in pregnant women, all with good results. 59−64 One concern is the uncertainty regarding development of antibodies to the TPO agent which, unlike those seen with romiplostim, might cross-react with endogenous TPO and create lasting. 74

Other thrombopoietic agents
Two current studies with avatrombopag and lusutrombopag, both of which were recently approved for procedures in thrombocytopenic patients with liver disease in the US, were careful to verify adequate pre-procedure portal flow and use only several days of TPO-RA prior to and during the procedure to avoid risks of thrombosis, especially that of the portal vein. Avatrombopag, an oral small molecule, apparently binds to the TPO-R similarly to eltrombopag, but does not have any dietary limitations. 81 It was shown to be effective in a phase II study of ITP, 81 and also in a recently published phase III trial, which confirmed the superiority of avatrombopag (5-40 mg daily) over placebo with regard to acute and durable platelet response in patients with chronic ITP. Headache was the most frequent side effect. 82 In view of the two RCT in ITP and the approved indication in liver disease, we expect that avatrombopag will be licensed for ITP.

A recombinant human thrombopoietin (rhTPO) has been licensed in China for many years in adults and children with ITP. Studies have also recently been performed in pregnant women, all with good results. 59−64 One concern is the uncertainty regarding development of antibodies to the TPO agent which, unlike those seen with romiplostim, might cross-react with endogenous TPO and create lasting.
and substantial thrombocytopenia in affected recipients. Importantly, neither romiplostim nor eltrombopag are recommended to be used in pregnancy; however, there are limited case reports in which the use of these agents in pregnant women with difficult ITP appeared to be safe.

**Future treatments for immune thrombocytopenia and the role of thrombopoietin receptor agonists**

The two TPO-RA licensed for use in ITP are now both licensed for use after one year from diagnosis after failure of corticosteroids, further consolidating their position as the mainstay for second-line therapy in ITP. However, many other agents are currently under development, at various stages of clinical testing, or are being considered for registration. Among these, fostamatinib, an inhibitor of spleen tyrosine kinase (syk) has an overall response rate of almost 50% with continued treatment, and an 18% rate of stable responses in heavily pretreated ITP patients. This agent was licensed in the US in 2018 for treatment of chronic ITP in adults. Several blockers of FcRn have entered trials in adults with persistent and chronic ITP; at least two (rozanolixizumab and ARGX-117) have completed phase II studies. The mechanism is a dramatic increase in IgG turnover as a result of inhibition of IgG recycling; not only “normal” but also IgG autoantibody levels decrease markedly. Preliminary results are encouraging but efficacy and toxicity need to be better defined in phase III studies. It remains to be seen how these agents will influence the future role of TPO-RA.

**Conclusion**

Romiplostim and eltrombopag are well tolerated and effective therapies for ITP with acceptable toxicity. Both agents increase the platelet count in up to three-quarters of patients. Ten years after their introduction, available evidence from short- and long-term and registry-based studies confirm the general safety of chronic long-term use of these medications, as well as persistent efficacy in most patients.

**References**

30. Kuter DJ, Mathias SD, Rummel M, et al. Health-related quality of life in nonspene-
patients with chronic idiopathic thrombocyto-
45. González-Lopez TJ, Alvareza-Roman MT, Pascuala C, et al. Use of eltrombopag for sec-
ondary immune thrombocytopenia in clinical prac-
topenia (ITP) treated with the thrombopo-
49. Bye NK, Wong RS, Thein MM, et al. A 2-
50. Jansens A, Rodeghiero F, Anderson D, et al. Changes in bone marrow morphology in adults receiving romiplostim for the treat-
52. Imbach F, Crowther M. Thrombopoietin-
55. Fenati P, Muus P, Kantarjian H, et al. Romiplostim monotherapy in thrombocy-
topenic patients with myelodysplastic syn-
56. Platbecker U, Wong RS, Veema A, et al. Safety and tolerability of eltrombopag ver-
sus placebo for treatment of thrombocy-
topenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, ran-
57. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag: Final Results from the Long-
58. Sevelius MT, Engebjerg MC, Farkas DK, et al. Risk of venous thromboembolism in patients receiving romiplostim or medical treatment? A retrospective collaborative survey from Italian hematol-
59. Cantoni S, Carpenedo M, Mazzucconi MG, et al. Alternate use of thrombopoietin recep-
tor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematol-
60. Mahervas M, Fatou O, Ebbo M, et al. The tem-
porary use of thrombopoietin receptor ago-
61. Newland A, Godeau B, Frigo V, et al. Remission and platelet responses with romi-
plostim in primary immune thrombocy-
62. Gonzalez-Lopez TJ, Pascal C, Alvarez-Roma

MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocy-
63. Ghadaki B, Nazi I, Kelton JG, Arnold DM. Sustained remissions of immune thrombo-
66. Sarpatwain A, Bennett D, Logie JW, et al. Thrombocytopenic events in patients with primary immune thrombocy-
67. Norgaard M, Seversin M, Lund Maegaard B, Jensen AO, Cha S, Sorenson HT. Risk of arterial thrombosis in patients with chronic primary immune thrombocy-

58. Sarpatwain A, Bennett D, Logie JW, et al. Thrombocytopenic events in patients with pri-